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ASSESSING GENETIC COUNSELORS’ CLINICAL APPROACH AND PRACTICES REGARDING
PATHOGENIC/LIKELY PATHOGENIC VARIANT DOWNGRADES
Grant William Bonesteele, BA
Advisory Professor: Jessica Corredor, MS, CGC
ABSTRACT
Although rare, variant downgrades from a pathogenic/likely pathogenic (P/LP) variant to a
variant of uncertain significance can have a significant impact on patients and their families in the
clinical cancer setting. However, there is a lack of literature about how to approach these potentially
challenging cases as a genetic counselor. Therefore, we aimed to characterize genetic counselors’
experiences, approach, and practices to variant downgrade cases using an online survey. The survey
asked participants how they would approach variant downgrade scenarios involving the CDH1 or ATM
genes with variable family histories. Genetic counselors appear to be united in whether they would
discuss how the variant reclassification was reached, the possibility of another reclassification in the
future, and implications for family members across the three variant downgrade scenarios. However,
there was variability regarding the management of the proband and the recruitment of family members
for family studies of the specific variant between variant downgrade scenarios. This difference in
participants’ approach could be attributed to factors such as family history or gene penetrance. Still,
participants exhibited the practice-based competencies outlined by ACGC and considered other factors in
addition to genetic testing results. We also explored potential challenges that genetic counselors face in
variant downgrade cases and found that most genetic counselors agree that counseling a patient who
underwent a risk-reducing surgery prior to the variant downgrade (91%) or a patient with a variant
downgrade in highly penetrant gene (64%) would be difficult. Common themes in genetic counselors’
experiences with variant downgrades included psychosocial concerns and challenges related to surgery
or family history. The genetic testing laboratory that performed testing was the most common resource
utilized by genetic counselors during variant downgrade cases. Ultimately, this study provides insight
iv

into how counselors approach variant downgrade cases, what challenges can occur, and what resources
would be helpful in these cases.
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INTRODUCTION
In the clinical cancer setting, hereditary cancer genetic testing has become an important aspect of
patient care. Clinical testing laboratories have adopted the consensus standards and guidelines for variant
interpretation published by the American College of Medical Genetics and Genomics (ACMG) and
Association for Molecular Pathology (AMP), and variant classifications are based on all the available
data at the time of testing. As such, genetic testing can identify variants that are classified as benign (B),
likely benign (LB), variant of uncertain significance (VUS), likely pathogenic (LP), and pathogenic (P).1
The identification of a P/LP variant related to an increased cancer risk may lead to changes in screening
or prevention recommendations for the patient depending on whether there are established guidelines for
management in a particular gene. For example, women identified with a P/LP variant in the BRCA1/2
genes are recommended to undergo breast MRIs/mammograms, risk-reducing mastectomy, and/or riskreducing bilateral salpingo-oopherectomy based on guidelines published by the National Comprehensive
Cancer Network (NCCN).2 On the other hand, NCCN and other professional organizations do not
recommend increased screening or prevention for patients based on B/LB/VUS. 1-3 As such, variant
interpretation and classification are integral to ensure proper management of a patient undergoing genetic
testing for a hereditary cancer syndrome.
There are nuances to the interpretation of genetic testing that make counseling these results more
challenging. Genetic counselors are trained to consider other factors when interpreting genetic test
results, such as a patient’s family history or the penetrance of a particular gene, as they can alter medical
management of a patient.4 For example, as outlined in the recently updated hereditary diffuse gastric
cancer (HDGC) guidelines, a patient with a suggestive family history and no P/LP variant identified in
the CDH1 or CTTNA1 gene is still recommended to undergo increased endoscopic screening.5
Furthermore, penetrance can impact cancer risk estimates and medical management recommendations.
For example, there is currently insufficient evidence for recommendations of preventative surgeries
based solely on the identification of a P/LP variant in moderately penetrant genes given the lower cancer
risks associated with these genes compared to highly penetrant genes.6,7 Yet some studies have shown
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that there is variability regarding patients’ surgical decisions when a VUS result is identified. This
variability may be explained by a combination of factors including prediction of cancer risk based on risk
models, family history, patient preference, and misunderstanding of VUS results. Collectively, these
studies illustrate the spectrum of factors to consider when interpreting and communicating genetic test
results and the importance of comprehensive genetic counseling.8,9
In addition to these challenges, interpretation of genetic testing results can be further
complicated by variant reclassifications. This is most prominent in cases regarding VUS results since, at
the moment of interpretation, there is insufficient evidence to define their impact on cancer risks.
However, as more evidence is collected, a VUS can be reclassified. Factors such as the presence or
absence of cancer in additional families with the variant and/or further functional studies can help with
variant reclassifications.1,10,11 The majority of VUSs are reclassified to a B/LB variant, and this type of
reclassification should have minimal clinical impact for a patient and their family because they are all
considered non-actionable results. Less frequently, a VUS can be reclassified to a P/LP variant which
can lead to increased cancer screenings or surgical recommendations.2,10,11
Even less frequently, variant downgrades, specifically a P/LP variant downgraded to a lower
classification, can occur.10,11 Although rare, studies have pointed out that variant downgrades can have a
significant impact on patients. Specifically, patients and their families may have followed rigorous
increased cancer screenings, underwent prophylactic surgeries, or made reproductive decisions that were,
in retrospect, not indicated based on genetic test results.12-14 Little is known about the perspective of
patients who had their P/LP variant downgraded, but one study described a patient who underwent riskreducing bilateral mastectomy after identification of a TP53 LP variant and expressed anger after it was
downgraded to a VUS.15 Furthermore, there is a lack of literature regarding genetic counselors’
experiences with and practices in these rare cases. Therefore, this study aims to assess genetic
counselors’ experiences with, and clinical approach and practices regarding cases that involve P/LP
downgrades in the clinical cancer setting. By characterizing genetic counselors’ experiences and
practices, we hope to better understand what challenges to anticipate, identify helpful resources, and
2

ultimately, better counsel patients and their families in these unique situations. Given the far-reaching
implications of variant downgrades on the patients and their families, research in this area can inform
genetic counselors’ approaches and improve patient outcomes in the future.
METHODS
Participants
Cancer genetic counselors who were full members of the National Society of Genetic Counselors
or American Board of Genetic Counseling (ABGC) were recruited via email and through the NSGC
Student Research Survey Program listserv. Participation in the survey constituted consent to the study,
and counselors could opt to discontinue at any point in the survey. The inclusion criteria consisted of (1)
being a board certified or board eligible genetic counselor in the US or Canada and (2) dedicating time
towards clinical cancer genetic counseling. These criteria excluded participants who had different
experience and expertise than required for this study. There were approximately 4,000 full members of
NSGC at the time of the study.
Procedures and Instrumentation
The survey was created by the authors using Qualtrics (Qualtrics, Provo, UT) available through
the University of Texas Health Science Center at Houston. It was distributed via email to members of
NSGC in August 2020. Two reminder emails were sent in September and October 2020. Due to low
participant recruitment, the survey was also distributed to the members of ABGC in October 2020. The
invitation to participate included: (a) purpose of the study; (b) time needed to complete the survey (~2025 minutes); (c) the option to confidentially provide an email address to be entered into a drawing to win
one of two $50 Amazon gift cards; and (d) the survey link. The survey was closed in January 2021.
The survey was a semi‐structured questionnaire with 51 questions. There were eight
demographic questions that collected information about schooling, workforce, and years of experience.
The next section evaluated genetic counselors’ experience with variant downgrade cases. Variant
downgrades were specifically defined as variants with a P/LP classification which was downgraded to a
3

lower classification (VUS, LB, B). This was differentiated from variant reclassifications which were
defined as variants that were reclassified to any other classification.
First, participants were asked how they would counsel a proband who was identified with a
BRCA1 VUS that was later reclassified to either a LB or P variant (Figure 1a). The next three scenarios
were randomized and assessed genetic counselors’ practices regarding variant downgrades involving LP
variants in the CDH1 or ATM genes and variable family histories (Figure 1b-d). For the purpose of this
study, one CDH1 scenario included a family history suggestive of HDGC defined as CDH1+fhx and the
other pedigree lacked a family history of gastric cancer and is defined as CDH1-fhx.

Figure 1a. BRCA1 VUS reclassification scenario: Participants
responded to how they would counsel the proband after the identification
of a BRCA1 VUS that was later reclassified to a likely benign or
pathogenic variant.
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Figure 1b. ATM scenario: Participants responded to how they would
counsel the proband after the identification of a likely pathogenic variant
in the ATM gene. The patient received increased breast cancer screening
prior to a variant downgrade from likely pathogenic to a VUS. Then
participants provided their counseling approach regarding the ATM
variant downgrade.

5

c)

d)

d)
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Figure 1c-d. CDH1+/-fhx scenarios: Participants responded to how they would counsel the proband after the identification of a likely pathogenic
variant in the CDH1 gene. The patient received increased breast cancer screening and a prophylactic gastrectomy prior to a variant downgrade from
likely pathogenic to VUS. Then participants provided their counseling approach regarding the CDH1 variant downgrade.

Figure 1. VUS reclassification and P/LP variant downgrade scenarios

We followed the hypothetical case scenarios with questions that asked participants to rate various variant
downgrade scenarios on a scale from very easy to very difficult. Lastly, genetic counselors who reported
experience with variant downgrade cases were asked about the challenges they encountered and the
resources they used (See appendix for complete copy of survey). All research protocols met the
requirements of the University of Texas Health Committee for the Protection of Human Subjects, and
this study was assigned approval number HSC-MS-20-0602.
Data Analysis
STATA (v13.1, College Station, TX) software was used to analyze statistics. Secondary
comparative analysis of participants’ answers between scenarios was performed using McNemar's test.
Specifically, McNemar’s test was used to evaluate if participants’ answers between scenarios were
different due to chance or due to differences among scenarios. All comparative tests were considered
significant at type I error rate of 5%. Free text responses were analyzed using inductive analysis, where
the data is coded independently of the specific questions that were asked of the participants and emerging
themes were identified.16 Free text responses were analyzed independently by primary investigators
(G.B. and G.T.) and highlighted. From the highlighted text, potential themes were identified
independently. The primary investigators consulted with each other to review the independently defined
themes and coding discrepancies were discussed until a consensus was reached.
RESULTS
Demographics
There were 1,159 cancer genetic counselors eligible to participate in this study based on the
NSGC professional status survey published in 2020.17 There were 165 responses to the survey, yielding
an estimated response rate of 14%. Of the 165 participants, 54 did not complete the variant downgrade
scenarios and were therefore excluded from analysis. Additionally, 24 participants were excluded from
the study because they met the exclusion criteria of working outside of the United States of America and
Canada or they did not work primarily in the clinical cancer setting. Ultimately, 87 responses were
7

included in the analysis. The majority of participants self-identified as female (81/87, 93.1%), nonHispanic (85/87, 97.7%), white or Caucasian (81/87, 93.10%), and they were employed at university
medical centers (39/87, 44.8%). This is representative of the respondents who participated in the 2020
NSGC Professional Status Survey, with the exception that a larger majority of our participants were
employed at a university medical center. Full demographic information is displayed in Table 1.17
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n (%)
Gender
Female

81 (93)

Male

6 (7)

White or Caucasian

81 (93)

Asian Indian

2 (2.5)

Asian

1 (1)

Other

2 (2.5)

Prefer not to answer

1 (1)

Race

Ethnicity
Non-Hispanic

85 (98)

Hispanic

1 (1)

Prefer not to answer

1 (1)

Institution Type
University medical center

39 (45)

University/nonmedical center

1 (1)

Public hospital/medical facility

19 (22)

Private hospital/medical facility

17 (19)

Diagnostic laboratory

4 (5)

Telegenetics company

4 (5)

Health maintenance organization

3 (3)

Number of years practicing in cancer genetics
<5 years

51 (59)

5-10 years

30 (34)

>10 years

6 (7)

Table 1. Demographics of participants (n=87)
9

Experience with Variant Downgrades
To better understand genetic counselors’ experience with variant downgrades, participants were
asked a series of questions regarding the number of patients they have counseled with variant
downgrades. Nearly 78% (68/87) of participants have had at least one variant downgrade case in their
career. In the year 2020, approximately 43% (37/87) of participants counseled 1-5 variant downgrade
cases compared to approximately 6% (5/87) who reported experience with counseling more than 25
variant downgrade cases. When looking at participants’ experience over their entire career, 32% (28/87)
of respondents counseled 1-5 variant downgrades, while 20% (18/87) indicated that they had counseled
over 25 cases in their career (Figure 2).
22%

# of cases counseled

None at all

1-5
6-10

7%

11-15

3%

43%

16%

5%
5%

16-20

33%
32%

7%

0%
1%

21-25
More than 25

20%

6%
0

10

20
30
% of participants

Downgrade cases over career

40

50

Downgrade cases this year

Figure 2. Participants’ experience with variant downgrades
BRCA1 VUS reclassification
Participants were asked a series of questions based on a hypothetical scenario involving a
BRCA1 VUS that was reclassified to a LB or P variant. A majority of participants agreed that risk
reducing mastectomy (80/87, 92%), risk reducing salpingo-oopherectomy (81/87, 93%), breast
MRI/mammogram (84/87, 98%), consideration of CA-125 and transvaginal ultrasounds (71/87, 82%), or
genetic testing for family members (82/87, 94%) were appropriate if the BRCA1 VUS was reclassified to
10

a pathogenic variant, but thought they were inappropriate if the BRCA1 VUS was reclassified to a likely
benign variant (Figure 3). Additionally, participants were more likely to change recommendations for the
proband’s family if the BRCA1 VUS was reclassified to a pathogenic variant, rather than a benign variant
(p<0.001) (Supplementary Table 1). Participants reported that variant reclassification and the proband’s
personal history were the most important factors influencing their counseling. However, a larger portion
of participants felt that the proband’s family history impacted their counseling when the BRCA1 VUS
was reclassified to a likely benign variant (Supplementary Figure 1)

Bilateral mastectomy

92%

5%

Bilateral salpingo-oopherectomy

93%

0%

Alternating breast MRI/mammogram every 6
months
Consideration of CA-125 and transvaginal
ultrasounds

98%

14%
82%

5%

Genetic testing of the proband's family members

94%

2%
0

BRCA1 VUS→pathogenic

20

40
60
80
percentage of participants

100

BRCA1 VUS→likely benign

Figure 3. Agreeance of participants on proband management after BRCA1 reclassification
CDH1 and ATM downgrades
In scenarios b-d, participants were asked a series of questions to characterize genetic counselors’
counseling approach regarding variant downgrades from a likely pathogenic variant to a VUS. These
scenarios involved a highly penetrant gene, CDH1 +fhx/-fhx and a moderately penetrant gene, ATM.
First, we assessed participants’ counseling approach to the likely pathogenic variant. Table 2
summarizes the information genetic counselors would discuss with patients in all three scenarios.
Genetic counselors were unified in their counseling approach with the exception of discussing
prophylactic surgery. While a vast majority of participants would discuss prophylactic surgery in both
CDH1 scenarios, only 34% of participants (30/87) would discuss this aspect in the ATM scenario.
11

CDH1+fhx

CDH1-fhx

ATM

n (%)

n (%)

n (%)

Discuss how the likely pathogenic classification
was reached (lines of evidence)

47 (54)

54 (62)

44 (51)

Discuss the possibility of variant reclassification

49 (56)

62 (71)

48 (55)

Discuss cancer risk estimates associated with a
germline likely pathogenic variant

85 (98)

84 (97)

84 (97)

Discuss implications for family members

85 (98)

84 (97)

83 (95)

Provide patient friendly resources

83 (95)

80 (92)

80 (92)

Discuss cancer screenings

84 (97)

84 (97)

76 (87)

Discuss prophylactic surgery

82 (95)

81 (94)

30 (34)

4 (5)

14 (16)

16 (18)

Counseling approach to a likely pathogenic
variant

Other

Table 2. Participant’s counseling approach to a likely pathogenic variant identified in the CDH1 or ATM
gene

If the likely pathogenic CDH1 variant was downgraded to a VUS, participants were less likely to
change the management for the proband in the CDH1+fhx scenario when compared to the other two
scenarios (p<0.001). A majority (28/37, 75%) of those who would change management between CDH1
scenarios indicated that family history was a factor in their decision making. Although the question
aimed to better understand why participants would change management for the proband, some
participants specified how they would change management, such as running risk models or obtaining
medical records of family members. (Supp. Fig 1D). On the other hand, participants responded similarly
between the CDH1-fhx and ATM scenario (p>0.05). A summary of the pair-wise comparisons and the
results of McNemar’s test can be found in Table 3.
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Yes, in both
scenarios

Yes/No

No/Yes

No, in both
scenarios

n(%)

n(%)

n(%)

n(%)

p-value

CDH1+fhx vs. CDH1-fhx

45 (52)

2 (2)

35 (40)

5 (6)

<0.001

CDH1+fhx vs. ATM

45 (52)

2 (2)

34 (39)

6 (7)

<0.001

CDH1-fhx vs. ATM

74 (85)

6 (7)

5 (6)

2 (2)

>0.05

With this specific variant
downgrade scenario, does this
change how you manage the
proband?

Table 3. Pair-wise comparison of whether participants would change management between the CDH1
scenarios and ATM scenario

After the variant downgrade, a majority of counselors would discuss how the variant
reclassification was reached, the possibility of another reclassification in the future, and implications for
family members. There appears to be variability in the responses regarding practices in the following
areas: continue recommended medical management based on guidelines, recruit family members to be in
a family study, and discuss how medical management is affected by the variant downgrade (Table 4).
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CDH1+fhx

CDH1-fhx

ATM

n (%)

n (%)

n (%)

Discuss how the variant reclassification was reached

80 (92)

82 (94)

79 (91)

Discuss the possibility of another variant reclassification
in the future

75 (86)

71 (82)

74 (85)

Continue recommended medical management based on
guidelines

70 (80)

31 (36)

48 (55)

Discuss implications for family members

81 (93)

81 (93)

72 (83)

Recruit family members to be in a family study for the
specific VUS (if eligible)

76 (87)

65 (75)

60 (69)

Discuss how medical management is affected by the
variant downgrade

40 (46)

57 (66)

59 (68)

5 (6)

4 (5)

2 (2)

Counseling approach if the likely pathogenic variant
was downgraded to a VUS

Other

Table 4. Participant’s counseling approach to a variant downgrade scenario
To better understand the variability in responses, McNemar’s test was performed to see if
participants changed their responses based on the gene or family history. Participants were more likely to
continue recommended medical management based on guidelines and less likely to discuss how medical
management was affected by the variant downgrade in the CDH1+fhx scenario. Along the same lines,
participants were more likely to discuss recruitment of family members for family studies in the
CDH1+fhx scenario compared to the CDH1-fhx and ATM scenarios (p<0.02 and p<0.002 respectively).
A summary of the pair-wise comparisons and McNemar’s test can be found in Table 5.
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Yes, in both
scenarios

Yes/No

No/Yes

No, in both
scenarios

n(%)

n(%)

n(%)

n(%)

p-value

CDH1+fhx vs. CDH1-fhx

28 (32)

42 (48)

3 (3)

14 (16)

<0.001

CDH1+fhx vs. ATM

44 (51)

26 (30)

4 (5)

13 (15)

<0.001

CDH1-fhx vs. ATM

23 (26)

8 (9)

25 (29)

31 (36)

<0.005

CDH1+fhx vs. CDH1-fhx

37 (43)

3 (3)

20 (23)

27 (31)

<0.001

CDH1+fhx vs. ATM

35 (40)

5 (6)

24 (28)

23 (26)

<0.001

CDH1-fhx vs. ATM

49 (56)

8 (9)

10 (11)

20 (23)

>0.05

CDH1+fhx vs. CDH1-fhx

61 (70)

15 (17)

4 (5)

7 (8)

<0.02

CDH1+fhx vs. ATM

56 (64)

20 (23)

4 (5)

7 (8)

<0.002

CDH1-fhx vs. ATM

56 (64)

9 (10)

4 (5)

18 (21)

>0.05

Would you discuss
continuation of
recommended medical
management based on
guidelines after the variant
downgrade?

Would you discuss how
medical management is
affected by the variant
downgrade

Would you discuss the
recruitment of family
members to be in a family
study of the specific VUS
after the variant
downgrade?

Table 5. Pair-wise comparison of whether participants would discuss aspects of management and
recruitment of family members for family studies between the CDH1 and ATM scenarios
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Challenges Associated with Variant Downgrades
When considering challenges associated with a variant downgrade, approximately 62%
(54/87) of participants characterized counseling a patient with a variant downgrade in a highly penetrant
gene as difficult or very difficult. Nearly 91% (78/87) of participants perceived counseling a patient who
received a prophylactic surgery before the variant downgrade occurred as difficult or very difficult. On
the other hand, counseling a patient with a variant downgrade in a moderately penetrant gene and
counseling the patient about how it affects the family were both characterized as neither easy nor
difficult by nearly 39% (34/87) and 40% (35/87) of participants, respectively. Finally, discussing how
the classification was reached (43/87, 49%) or how it affects medical management (38/87, 44%) was
considered easy by most participants (Figure 4). Of the 68 participants with variant downgrade
experience, a majority (36/68, 53%) experienced challenges while counseling a patient with a variant
downgrade. Inductive analysis was performed on free-text responses describing those challenges and
multiple prevalent themes were identified. Many participants (14/68, 21%) indicated that psychosocial
concerns were a challenge. Nearly 10% (7/68) of participants noted challenges related to surgery, while
7% (5/68) encountered challenges related to family history. Another 7% (5/68) also noted challenges
related to patients’ hesitations about reduced screening. Several quotes from our participants are
highlighted in Figure 5.
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Counseling a patient with a variant downgrade in a highly penetrant gene (i.e.BRCA1, BRCA2, CDH1, TP53)

5% 10%

Counseling a patient with a variant downgrade in a moderately penetrant gene
3%
(i.e.-ATM, CHEK2)

23%

21%

16%

39%

Discussing how the classification was reached with a patient who received a
4%
variant downgrade

17

46%

37%

45%

37%

14%
2%

Discussing how a variant downgrade in a clinically actionable variant affects
medical management for a patient

7%

Counseling a patient about how the variant downgrade affects management of
their family members

8%

37%

38%

3%
Counseling a variant downgrade to a patient who underwent a prophylactic
surgery based on identification of a gene variant that was initially classified as
4%
pathogenic or likely pathogenic
2%
Counseling a variant downgrade to a patient who has been receiving increased
cancer screenings/surveillance based on identification of a gene variant that was
21%
initially classified as pathogenic or likely pathogenic
2%

0
Very easy

32%

22%

40%

41%

14%

50%

37%

20
Easy

40
Neither easy nor difficult

Figure 4. Potential challenges associated with providing genetic counseling for patients with variant downgrade

36%

60

4%

80
Difficult

100

Very difficult

Psychosocial concerns
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“Patient who had done a
prophylactic surgery was
extremely upset as this
was an action that could
not be reversed, she had
major complications from
her surgery and felt it was
all for nothing”

“When the patient's primary
feeling is of disbelief or
regret. It can be difficult to
‘convince’ them of the new
data.”

Challenges related to
surgery

Challenges related to
family history

Hesitations about reduced
screening

“The most challenging
scenarios are when
patients have either
already pursued
prophylactic surgeries or
are in the processing of
planning a procedure…”

“….Patient is confused
and opted to continue with
increased monitoring
given fhx”

“Patients have become
accustomed to their
previously thought cancer
risks and felt protected by
the increased
surveillance…. and also
feel
uncomfortable/worried
about pulling back on
cancer screening”.

“It's much harder once a
patient has had prophylactic
surgery based on a variant
downgrade.”

“The downgrade from P/LP
to VUS is especially
challenging in families
where the family history
appears consistent with the
gene in which there is a
VUS.”

“Hesitations from patient,
particularly in the setting of
desiring the increased
screening they have
previously received”

Figure 5. Summary of themes identified by qualitative inductive analysis of potential challenges presented by participant

Resources
The most common resources utilized by participants included the primary genetic testing
laboratory, other genetic testing laboratories, disease databases, and other genetic counseling colleagues.
This was consistent across the CDH1+/-fhx and ATM scenarios and the findings are summarized in
Supplemental Material 5.
DISCUSSION
Studies in both commercial laboratory and hereditary cancer clinic settings show that only 0.3%
of P/LP variants are downgraded to a VUS.10,11 Although rare, P/LP variant downgrades can pose a
significant challenge for patients and their medical management.12-14 However, little is known about
genetic counselors’ insights regarding these unique cases. Thus, this study sought to address the lack of
knowledge in this area. Interestingly, responses from this study support that these rare cases can be
difficult to navigate for genetic counselors. Participants report that it would be difficult for them to
counsel a variant downgrade case, specifically if it involves a highly penetrant gene such as BRCA1 or
CDH1. Though this perception of difficulty appears to change depending on the penetrance of the gene
as participants see counseling a moderately penetrant gene as neither easy nor difficult. The difference in
difficulty may be attributed to the difference in management recommendations. For example, moderately
penetrant genes tend to have more conservative surgery recommendations due to their relatively lower
cancer risk, when compared to highly penetrant genes.6,7,18 Thus, a variant downgrade in a moderately
penetrant gene may be less complicated from a surgical recommendation standpoint and may be seen as
relatively easier to counsel. This is supported by our findings that nearly 91% (78/87) of participants find
counseling a patient who had received a prophylactic surgery prior to the variant downgrade to be a
difficult challenge. Furthermore, genetic counselors who have experience counseling patients who
underwent prophylactic surgery prior to a variant downgrade pointed out that most of the difficulties
stem from psychosocial concerns such as regret and uncertainty.
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Similar challenges related to uncertainty can also be seen in cases involving VUS results.8,9 This
is because clinical recommendations can change based on whether the VUS is reclassified to a nonactionable or actionable variant.1-3,19 As expected, a vast majority of genetic counselors practiced
according to professional guidelines that recommend increased breast screening (84/87, 98%) and option
for prophylactic mastectomy (80/87, 92%) if the VUS was reclassified to an actionable BRCA1 variant,
but not if the variant was reclassified to a non-actionable variant. Participants’ responses from this study
demonstrate that genetic counselors rely on patients’ personal and family histories as guides to give
recommendations in the event a VUS is reclassified to a LB variant. On the other hand, when a VUS is
reclassified to a P variant, then the actionability of the genetic test result is what guides medical
management recommendations. Ultimately, this data supports that genetic counselors are unified in their
approach to VUS reclassifications and practice according to professional guidelines. This could be
attributed to genetic counselors’ experience with VUS results and the presence of professional guidelines
to help manage patients identified with a VUS.
CDH1 and ATM pre-downgrade scenarios
Similarly, when genetic testing results are straightforward with a clear P/LP variant identified in
hereditary cancer predisposition genes, it appears that genetic counselors are uniform in certain aspects,
such as discussing cancer risk estimates, cancer screenings, implications for family members, and
resources, regardless of the gene or family history. On the other hand, there appears to be more
disagreement between participants in the practice of discussing prophylactic surgery, how the variant
classification was reached, and the possibility of reclassification in the future. A minority of participants
would discuss prophylactic surgery in the ATM scenario, and this is expected because there is no data to
support the benefit of prophylactic surgery in these cases.7 However, the difference among participants in
whether or not they discuss how the variant classification was reached and the possibility of
reclassification in the future is noteworthy. As defined by ACMG/AMP guidelines, likely pathogenic
implies over 90% certainty that the variant is disease causing, rather than complete certainty. If it is the
only evidence concerning of a genetic disorder, recommendations are to explain the finding carefully to
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families.1 Furthermore, it has also been suggested that providers educate patients on the chances of a
variant downgrade from an actionable variant to a non-actionable variant because of its impact on
management.10 Participants’ hesitation to provide information about the variant classification and the
chances of reclassification when cases involve LP variants suggests that these aspects are not routinely
incorporated into genetic counselors’ clinical practice when an actionable result is identified.
CDH1 and ATM post-downgrade scenarios
Genetic counselors are united in certain areas of practice when it comes to cases involving a LP
variant that was downgraded to a VUS. For these variant downgrade scenarios, it appears to be common
practice for genetic counselors to discuss implications for family members, how the variant
reclassification was reached, and the possibility of reclassification in the future. Additionally, genetic
counselors are unified in the resources they would use in cases of variant downgrades. Prior research has
explored what resources genetic counselors use for VUS results, and Scherr et. al (2015) found that
genetic counselors would contact the genetic testing laboratory directly, use supplemental reports from
the laboratory, discuss the results with a colleague, or search scientific literature.27 Our study
demonstrates that genetic counselors would utilize similar resources even in cases of variant downgrades.
On the other hand, there was disagreement among participants regarding discussions about
medical management recommendations for the proband and recruitment of family members for family
studies. Specifically, participants had variable responses in whether they would discuss continued
medical management based on guidelines for the proband, how medical management is affected by the
variant downgrade, and whether or not they would recommend changing the management of the proband
between variant downgrade scenarios. These results differ from the previous assessment of the BRCA1
VUS reclassification scenarios, where genetic counselors were united in their approach with regards to
management. The concordance in those scenarios could be attributed to the availability of professional
guidelines that provide guidance for management of patients identified with a definitive result, either
non-actionable or actionable.1-3,5,7 However, this data suggests that medical management
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recommendations for a proband may be less clear when a causative variant is identified and later
reclassified to a non-actionable result.
To better understand the variability observed in participants’ responses regarding patient
management and recruitment of family members for family studies, further comparisons were made to
see if participants altered their approach in these areas depending on the specific gene discussed or the
family history. When comparing management decisions between the two CDH1 scenarios, genetic
counselors were more likely to discuss aspects of management differently depending on the presence of a
suggestive family history. These counseling practices are expected given that family history is an
important consideration for HDGC. Under the previous HDGC guidelines published in 2015, families
could have a clinical diagnosis of HDGC based on reported family history even without an identifiable
CDH1 variant or with a CDH1 VUS. Based on the 2015 clinical practice guidelines, these families are
still recommended to be followed by a team with expertise in HDGC and receive endoscopic
surveillance.20 However, recent updates have differentiated HDGC as the presence of a pathogenic
variant in the CDH1 gene with a reported family history of diffuse gastric cancer, while “HDGC-like”
was created to encompass families who meet testing criteria for HDGC but have no identified
CDH1/CTNNA1 variant.5 Although gastric cancer surveillance recommendations do not differ
significantly between these two guidelines for patients with an identified CDH1 VUS, the updated
guidelines specifically state that prophylactic gastrectomy is not advised for these individuals/families. 5
As such, genetic counselors may have different management recommendations for the proband among
the CDH1 scenarios depending on the family history presented in the scenario and/or which practice
guidelines they are following. Ultimately, it appears that family history and its interpretation within
professional guidelines can affect how genetic counselors counsel patients with variant downgrades from
clinically actionable to non-actionable variants.
In contrast, when the CDH1 scenarios were compared to the ATM scenario, it was less certain
what factors contributed to the difference in practices among genetic counselors. Participants were more
likely to discuss how recommended medical management would continue based on guidelines and
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recruitment of family members for family studies in the CDH1+fhx scenario. This is consistent with
recommendations outlined by the HDGC clinical practice guidelines mentioned previously.5 Therefore, a
suggestive family history could influence genetic counselors to continue recommended medical
management based on guidelines and to consider family testing in other affected family members to
clarify if the variant is causative. Alternatively, cancer risks associated with moderately penetrant genes,
such as ATM, are relatively lower compared to highly penetrant genes. As such, individuals identified
with a P/LP variant in a moderately penetrant gene could present with variable family histories.7,21
Therefore, once a LP variant in the ATM gene is downgraded to a VUS, medical management is expected
to change in the absence of a family history of cancer. Still, it is unknown exactly what factors
influenced genetic counselors to counsel differently between the CDH1 and ATM downgrade scenarios.
Genetic counselors could have been influenced by multiple factors including, but not limited to, gene
penetrance, family history, and/or availability of clinical practice guidelines. Therefore, although our
study did not explicitly include questions to better understand how gene penetrance could have affected
the study participants’ counseling practices in these specific variant downgrade cases, gene penetrance
may have been a contributing factor in decision making.
Limitations
There are several limitations to consider in this study. First, genetic counselors with strong
opinions about variant downgrade cases or who are more experienced with cases involving variant
downgrades may have been more likely to respond to this survey and cause a selection bias.
Furthermore, this survey was not a formally validated tool and was created by the authors which could
have led some participants to interpret questions differently than intended. For example, qualitative
analysis shows that some participants answered why while others answered how they would change
management for a proband after a variant downgrade occurs. Given that approximately 59% of our
participants had less than 5 years of experience in the cancer field and the rarity of a variant downgrade,
a majority of participants were expected to have 1-5 cases at most this year and throughout their career.
However, a large number of participants (18/87, 20%) indicated that they counseled 25 or more variant
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downgrade cases throughout their career. Although unlikely, one possibility is that variant downgrades
cases are underreported. Although variant downgrades and variant reclassifications were defined for the
purposes of the survey, participants could have based their answers on their own definitions. If
participants did misinterpret these definitions, genetic counselors’ experience with variant downgrade
cases may be misrepresented. Lastly, this survey did not consider the recently updated HDGC guidelines,
which were published shortly before distribution of the survey. Counseling approaches could have
differed among participants depending on whether or not participants agree on which CDH1 scenarios
met HDGC criteria. Therefore, it is possible that participants’ responses may have differed depending on
which HDGC practice guidelines they are following.
Practice Implications and Future Research
This is the first study, to our knowledge, that describes the specific approach and practices of
genetic counselors when they encounter a variant downgrade case, and the perceived and reported
challenges that are associated with it. In this study, most genetic counselors characterize counseling a
patient with a variant downgrade as either difficult or very difficult, especially if it involves a highly
penetrant gene or a patient who received prophylactic surgery before the downgrade. There are aspects
for which genetic counselors are unified in their practices with regards to variant downgrade cases.
Genetic counselors seem to be exhibiting practice-based competencies outlined by ACGC which
includes using pedigree analysis, inheritance patterns, genetic epidemiology, and other pertinent
information to assess risk for a genetic condition. Furthermore, they are critically assessing literature and
other sources of information for utilization during counseling sessions, as expected.4 However, it is
important to note that there was relatively more discordance in how a patient was managed in these
variant downgrade scenarios. Family history appears to be just one of the factors that influence genetic
counselors’ approach to these cases, but gene penetrance and other factors may influence these practices
as well. That being said, future research in this area can better characterize genetic counselors’
motivations behind their approach to variant downgrade cases. The variability in the patient’s
management also suggests a possible need for practice guidelines to assist genetic counselors in variant
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downgrade scenarios. As such, future studies should examine the desire for practice guidelines or other
resources to aid genetic counselors in cases involving variant downgrades.
Another area for future research is our limited understanding of patients’ perspectives in the
variant downgrade setting. To our knowledge, there is only one study that explored patients’ perspectives
about reclassification, and only one of the 20 participants in the study experienced a variant downgrade.
By exploring patients’ perspectives and potential needs in the variant downgrade setting, genetic
counselors can gain insights from the patients’ point of view into whether there are unmet needs based
on the current practicing approach or if there are any aspects of counseling that need improvement.
Although this study did not explore these aspects of variant downgrades, this study contributed to the
current literature regarding important considerations during variant downgrade cases. Further studies will
expand our knowledge on this topic and in turn, help improve patient outcomes.
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APPENDIX
Copy of Qualtrics Survey
1. Where do you currently practice as a genetic counselor?
o United States
o Canada
o Other
2. How much of your time is currently dedicated to cancer genetic counseling?
o 1-25%
o 26-50%
o 51-75%
o 76-100%
o None at all
3. What is your gender?
o Male
o Female
o Other
o Prefer not to answer
4. What is your age?____________
5. What is your race? Select all that apply.
o American Indian or Alaskan Native
o Asian
o Asian Indian
o Black or African American
o Native Hawaiian or other Pacific Islander
o White or Caucasian
o Prefer not to answer
6. What is your ethnicity?
o Hispanic
o Non-Hispanic
o Prefer not to answer
7. Please enter your graduation year from a genetic counseling training program.
______________
8. In what region do you practice?
o Region 1: CT, MA, ME, NH, RI, VT, CN, Maritime Provinces
o Region 2: DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI, Quebec
o Region 3: AL, FL, GA, KY, LA, MS, NC, SC, TN
o Region 4: AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI, Ontario
o Region 5: AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, Sask.
o Region 6: AK, CA, HI, ID, NV, OR, WA, British Columbia, Yukon
9. Please select which best describes your primary place of employment (Select one):
o University medical center
o University/nonmedical center
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o
o
o
o
o
o
o

Private hospital/medical facility
Public hospital/medical facility
Physician’s private practice
Diagnostic laboratory
Health maintenance organization
Telegenetics company
Other (please specify) (blank text box)

10. How many years in total have you practiced as a clinical cancer genetic counselor?
______________
Definitions for the purpose of this survey
Genetic testing can identify genetic variants that are classified as benign, likely benign, variant of
uncertain significance (VUS), likely pathogenic, and pathogenic.
Variant reclassification: A variant that is changed from one classification to another classification (i.e.
– a VUS to a benign variant classification, or a pathogenic to a likely pathogenic classification).
Variant downgrade: A variant with a pathogenic or likely pathogenic classification that is
downgraded to a lower classification (i.e. – a pathogenic to a VUS classification, or a likely pathogenic
to a VUS classification)
Actionable variants: Pathogenic or likely pathogenic variants that can change medical management or
treatment based on genetic test results (i.e. – increased cancer screening/surveillance, recommendations
for preventative surgeries or targeted treatment, etc.).
Non-actionable variants: VUS, likely benign, or benign variants that do not change medical
management or treatment (i.e. – general population cancer screening/surveillance, etc.)
11. Which of the following best represents the discussions within your department/institution
regarding variant downgrades in your clinics?
o Our department/institution has not had discussions regarding this topic
o Our department/institution has had discussions, but a consensus was not reached on how
to address variant downgrades in our clinics
o Our department/institution has developed formal policies (i.e. standard of practice)
regarding how to address variant downgrades in our clinics
o Other, please specify: ___________
12. How many patients have you counseled regarding a variant reclassification this year?
o 1-10
o 11-20
o 21-30
o 31-40
o 41-50
o More than 50
o None at all
13. How many patients have you counseled regarding a variant downgrade this year?
o 1-5
o 6-10
o 11-15
o 16-20
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o
o
o

21-25
More than 25
None at all

14. How many patients have you counseled regarding a variant downgrade over the span of your
genetic counseling career?
o 1-5
o 6-10
o 11-15
o 16-20
o 21-25
o More than 25
o None at all
15. How comfortable are you counseling a patient with a variant downgrade? (very uncomfortable,
uncomfortable, neither uncomfortable nor comfortable, comfortable, very comfortable)

You are counseling this proband. She received genetic testing from her genetic counselor 4 years ago and
the results revealed a VUS in the BRCA1 gene. The results were reclassified to a likely benign variant.
16. Which of the following recommendations would be appropriate for the proband based on the
variant reclassification? Select all that apply.
o Bilateral mastectomy
o Bilateral salpingo-oophorectomy
o Alternating breast MRI/breast mammogram every 6 months
o Consideration of serum CA-125 and transvaginal ultrasounds
o Genetic testing of the proband’s family members
o None of the above
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17. Would you recommend changing the medical management for the proband’s family members
based on the variant reclassification?
o Yes. please specify: ______________
o No. please explain: ______________
18. Which of the following factors influence your counseling in this specific variant reclassification
scenario? Select all that apply.
o The proband’s personal history
o The proband’s family history of cancer
o The BRCA1 likely benign variant
o Other, please specify: ______________
Consider a different scenario for this same proband. The proband’s BRCA1 VUS was reclassified to a
pathogenic variant.
19. Which of the following recommendations would be appropriate for the proband based on the
variant reclassification? Select all that apply.
o Bilateral mastectomy
o Bilateral salpingo-oophorectomy
o Alternating breast MRI/breast mammogram every 6 months
o Consideration of serum CA-125 and transvaginal ultrasounds
o Genetic testing of the proband’s family members
o None of the above
20. Would you recommend changing the medical management for the proband’s family members
based on the variant reclassification?
o Yes. please specify: ______________
o No. please explain: ______________
21. Which of the following factors influence your counseling in this specific variant reclassification
scenario? Select all that apply.
o The proband’s personal history
o The proband’s family history of cancer
o The BRCA1 pathogenic variant
o Other, please specify: ______________
22. How comfortable are you with disclosing CDH1 genetic test results to a patient according to
each of the following results? (Very uncomfortable, uncomfortable, neither uncomfortable nor
comfortable, comfortable, very comfortable)
o Pathogenic
o Likely pathogenic
o Variant of unknown significance (VUS)
o Likely benign
o Benign
23. How comfortable are you with disclosing ATM genetic test results to a patient according to each
of the following results? (Very uncomfortable, uncomfortable, neither uncomfortable nor
comfortable, comfortable, very comfortable)
o Pathogenic
o Likely pathogenic
o Variant of unknown significance (VUS)
o Likely benign
o Benign
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You are counseling this proband. The proband has no personal history of cancer. You previously ordered
genetic testing for the proband due to her family history of lobular breast cancer, diffuse gastric cancer,
and colon cancer. The genetic test revealed a likely pathogenic variant in the CDH1 gene. She reports a
history of normal breast screenings. She has never had an Esophagogastroduodenoscopy (EGD) or any
stomach biopsies. She reports no one in her family has ever undergone genetic testing. Consider the
following questions and answer according to how you would approach this in your clinical practice.
24. Is the proband’s family history suggestive of Hereditary Diffuse Gastric Cancer (HDGC)?
o Yes
o No
25. How would you counsel the proband when genetic testing identifies a likely pathogenic variant
in the CDH1 gene? Select all that apply.
o Discuss how the likely pathogenic classification was reached (lines of evidence)
o Discuss the possibility of variant reclassification
o Discuss cancer risk estimates associated with a germline CDH1 likely pathogenic variant
o Discuss implications for family members
o Provide patient friendly resources
o Discuss cancer screenings
o Discuss prophylactic surgery
o Other, please specify: _________________
If “Discuss cancer screenings” was selected……
26. Which of the following cancer screenings would you discuss with the proband when genetic
testing identifies a likely pathogenic variant in the CDH1 gene? Select all that apply.
o Discuss breast cancer screening (clinical breast exam, annual breast mammogram or
breast MRI)
o Discuss stomach cancer screening (surveillance endoscopy with biopsy)
o Discuss colon cancer screening (colonoscopy)
o Other, please specify: __________
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If “Discuss prophylactic surgery” was selected……
27. Which of the following cancer screenings would you discuss with the proband when genetic
testing identifies a likely pathogenic variant in the CDH1 gene? Select all that apply.
o Discuss risk-reducing mastectomy
o Discuss risk-reducing total gastrectomy
o Other, please specify: __________
Consider a scenario where the proband’s CDH1 likely pathogenic variant was downgraded to a VUS 4
years later. In that time, the proband has been receiving increased breast cancer screenings (alternating
mammograms and breast MRIs every 6 months). Moreover, she underwent risk reducing total
gastrectomy.
28. With this specific variant downgrade scenario, does this change how you manage the proband?
o Yes. please specify: ______________
o No. please explain: ______________
29. With this specific variant downgrade scenario, which resources would you utilize to prepare for
your session? Select all that apply.
o Review primary literature
o Gather information from primary testing laboratory on how variant reclassification was
reached
o Gather information from other genetic testing laboratories on their classification of the
variant
o Consult NSGC/Cancer SIG listservs
o Consult other genetic counselors
o Review databases (e.g. ClinVar, OMIM, DECIPHER)
o Other, please specify: _________________
30. How would you counsel the proband after the likely pathogenic variant in the CDH1 gene is
downgraded to a VUS? Select all that apply.
o Discuss how the variant reclassification was reached
o Discuss the possibility of another variant reclassification in the future
o Discuss that the proband and her family meet the clinical criteria for HDGC
o Continue recommended medical management based on guidelines
o Discuss implications for family members
o Recruit family members to be in a family study for the specific CDH1 VUS (if eligible)
o Discuss how medical management is affected by the variant downgrade. If so, please
specify: ______________
o Other, please specify: _________________
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You are counseling this proband. The proband has no personal history of cancer. You previously ordered
genetic testing for the proband due to her family history of breast cancer. The genetic test revealed a
likely pathogenic variant in the CDH1 gene. She reports a history of normal breast screenings. She has
never had an Esophagogastroduodenoscopy (EGD) or any stomach biopsies. She reports no one in her
family has ever undergone genetic testing. Consider the following questions and answer according to
how you would approach this in your clinical practice.
31. Is the proband’s family history suggestive of Hereditary Diffuse Gastric Cancer (HDGC)?
o Yes
o No
32. How would you counsel the proband when genetic testing identifies a likely pathogenic variant
in the CDH1 gene? Select all that apply.
o Discuss how the likely pathogenic classification was reached (lines of evidence)
o Discuss the possibility of variant reclassification
o Discuss cancer risk estimates associated with a germline CDH1 likely pathogenic variant
o Discuss implications for family members
o Provide patient friendly resources
o Discuss cancer screenings
o Discuss prophylactic surgery
o Other, please specify: _________________
If “Discuss cancer screenings” was selected……
33. Which of the following cancer screenings would you discuss with the proband when genetic
testing identifies a likely pathogenic variant in the CDH1 gene? Select all that apply.
o Discuss breast cancer screening (clinical breast exam, annual breast mammogram or
breast MRI)
o Discuss stomach cancer screening (surveillance endoscopy with biopsy)
o Discuss colon cancer screening (colonoscopy)
o Other, please specify: __________
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If “Discuss prophylactic surgery” was selected……
34. Which of the following cancer screenings would you discuss with the proband when genetic
testing identifies a likely pathogenic variant in the CDH1 gene? Select all that apply.
o Discuss risk-reducing mastectomy
o Discuss risk-reducing total gastrectomy
o Other, please specify: __________
Consider a scenario where the proband’s CDH1 likely pathogenic variant was downgraded to a VUS 4
years later. In that time, the proband has been receiving increased breast cancer screenings (alternating
mammograms and breast MRIs every 6 months). Moreover, she underwent risk reducing gastrectomy.
35. With this specific variant downgrade scenario, does this change how you manage the proband?
o Yes. please specify: ______________
o No. please explain: ______________
36. With this specific variant downgrade scenario, which resources would you utilize to prepare for
your session? Select all that apply.
o Review primary literature
o Gather information from primary testing laboratory on how variant reclassification was
reached
o Gather information from other genetic testing laboratories on their classification of the
variant
o Consult NSGC/Cancer SIG listservs
o Consult other genetic counselors
o Review disease databases (e.g. ClinVar, OMIM, DECIPHER)
o Other, please specify: _______________
37. How would you counsel the proband after the likely pathogenic variant in the CDH1 gene is
downgraded to a VUS? Select all that apply. Select all that apply.
o Discuss how the variant reclassification was reached
o Discuss the possibility of another variant reclassification in the future
o Discuss that the proband and her family meet the clinical criteria for HDGC
o Continue recommended medical management based on guidelines
o Discuss implications for family members
o Recruit family members to be in a family study for the specific CDH1 VUS (if eligible)
o Discuss how medical management is affected by the variant downgrade. If so, please
specify:________________
o Other, please specify: _________________

33

You are counseling this proband. The proband has no personal history of cancer. You previously ordered
genetic testing for the proband due to her paternal aunt’s history of breast cancer. The genetic test
revealed a likely pathogenic variant in the ATM gene. The proband reports a history of normal breast
screenings. She reports no one in her family has ever undergone genetic testing. Consider the following
questions and answer according to how you would approach this in your clinical practice.
38. In this scenario, what recommendations would be appropriate for the proband? Select all that
apply.
o Breast MRI/mammogram every 6 months
o Risk reducing mastectomy
o I would not recommend increased cancer screening surveillance/risk reducing surgeries
to the proband
39. How would you counsel the proband when genetic testing identifies a likely pathogenic variant
in the ATM gene? Select all that apply.
o Discuss how the likely pathogenic classification was reached (lines of evidence)
o Discuss the possibility of variant reclassification
o Discuss cancer risk estimates associated with a germline ATM likely pathogenic variant
o Discuss implications for family members
o Provide patient friendly resources
o Discuss cancer screenings. If so, please specify:_____________
o Discuss prophylactic surgery. If so, please specify:___________
o Other, please specify: _________________
Consider a scenario where the proband’s ATM likely pathogenic variant was reclassified to a VUS 4
years later. In that time, the proband underwent increased breast cancer screening surveillance.
40. With this specific variant downgrade scenario, does this change how you manage the proband?
o Yes. please specify: ______________
o No. please explain: ______________
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41. With this specific variant downgrade scenario, which resources would you utilize to prepare for
your session? Select all that apply.
o Review primary literature
o Gather information from testing laboratory on how variant reclassification was reached
o Gather information from other genetic testing laboratories on their classification of the variant
o Consult NSGC/Cancer SIG listservs
o Consult other genetic counselors
o Review disease databases (e.g. ClinVar, OMIM, DECIPHER)
o Other, please specify: _________________
42. How would you counsel the proband after the likely pathogenic variant in the ATM gene is
downgraded to a VUS? Select all that apply.
o Discuss how the variant reclassification was reached
o Discuss the possibility of another variant reclassification in the future
o Continue recommended medical management based on guidelines
o Discuss implications for family members
o Recruit family members to be in a family study for the specific ATM VUS (if eligible)
o Discuss how medical management is affected by the variant downgrade. If so, please
specify:_______________
o Other, please specify: _________________
Please indicate how easy or difficult you find the following scenarios involved in counseling a variant
downgrade Very easy, easy, neutral, difficult, very difficult)
43. Counseling a patient with a variant downgrade in a highly penetrant gene. (i.e.-BRCA1, BRCA2,
TP53, CDH1)
44. Counseling a patient with a variant downgrade in a moderately penetrant gene. (i.e.-ATM,
CHEK2)
45. Discussing how the classification was reached with a patient who received a variant downgrade.
46. Discussing how a variant downgrade in a clinically actionable variant affects medical
management.
47. Counseling a variant downgrade to a patient who underwent a prophylactic surgery based on
identification of a gene variant that was initially classified as pathogenic or likely pathogenic.
48. Counseling a variant downgrade to a patient who has been receiving increased cancer
screenings/surveillance based on identification of a gene variant that was initially classified as
pathogenic or likely pathogenic.
49. Counseling a patient about how the variant downgrade affects management of their family
members.
50. Did you experience any challenges when counseling a patient about variant downgrades?
o Yes→ Please explain
o No
51. What resources did you find helpful as you counseled your patient(s) about variant downgrades?
(free response)
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52. Please enter your e-mail address if you wish to be entered into the drawing for one of two $50
Amazon gift cards.

Yes, in both
scenarios Yes/No

No/Yes

No, in both
scenarios

n(%)

n(%)

n(%)

n(%)

p-value

6 (7)

77 (84)

0(0)

4 (5)

<0.001

Would you recommend changing the
medical management for the proband’s
family members based on the variant
reclassification?
BRCA1 pathogenic variant vs. BRCA1
likely benign variant reclassification

Supplementary Table 1. Pair-wise comparison of whether participants would change the medical
management for the proband’s family in the BRCA1 reclassification scenario

98%

BRCA1 reclassification

70%
31%

Family history

57%
60%

Proband's personal history

70%
0

20

40
60
% of participants

BRCA1 VUS→pathogenic
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100

BRCA1 VUS→ likely benign

Supplementary Figure 1. Factors that influenced counseling in the BRCA1 reclassification scenarios
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64%

Review primary literature

76%
79%
97%
97%
94%

Gather information from testing laboratory on how variant
reclassification was reached

89%
92%
93%

Gather information from other genetic testing laboratories on their
classification of the variant
33%

Consult NSGC/Cancer SIG listservs
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49%

57%
66%

Consult other genetic counselors

87%
89%
85%
89%
87%

Review disease databases (e.g. ClinVar, OMIM, DECIPHER)
2%

Other

8%
9%

0

ATM

CDH1-fhx

20
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60
% of participants

CDH1+fhx

Supplementary Figure 2. Resources utilized by genetic counselors during variant downgrade case
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